14,000 Shares in Neos Therapeutics, Inc. (NEOS) Purchased by State of Wisconsin Investment Board

State of Wisconsin Investment Board acquired a new stake in shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,000 shares of the company’s stock, valued at approximately $102,000. State of Wisconsin Investment Board owned approximately 0.06% of Neos Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in NEOS. Teachers Advisors LLC lifted its holdings in Neos Therapeutics by 16.3% during the 4th quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Neos Therapeutics by 15.5% during the 1st quarter. Russell Investments Group Ltd. now owns 100,783 shares of the company’s stock valued at $725,000 after buying an additional 13,527 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Neos Therapeutics by 130.3% during the 1st quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock valued at $346,000 after buying an additional 27,174 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Neos Therapeutics by 37.1% during the 1st quarter. Bank of New York Mellon Corp now owns 59,841 shares of the company’s stock valued at $431,000 after buying an additional 16,191 shares in the last quarter. Finally, Hunter Associates Investment Management LLC bought a new stake in Neos Therapeutics during the 1st quarter valued at about $360,000. Institutional investors own 44.29% of the company’s stock.

Neos Therapeutics, Inc. (NEOS) opened at 9.20 on Friday. The firm’s 50-day moving average is $9.01 and its 200-day moving average is $7.65. The stock’s market cap is $258.34 million. Neos Therapeutics, Inc. has a 52-week low of $4.85 and a 52-week high of $9.25.

Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.83) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The company had revenue of $4.91 million for the quarter. Equities research analysts predict that Neos Therapeutics, Inc. will post ($3.10) earnings per share for the current year.

A number of equities research analysts recently weighed in on the stock. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 20th. BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price objective on shares of Neos Therapeutics in a report on Tuesday, June 20th. Zacks Investment Research lowered shares of Neos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. Cantor Fitzgerald set a $20.00 price objective on shares of Neos Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the company an “outperform” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Neos Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $13.83.

WARNING: This news story was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://transcriptdaily.com/2017/09/17/14000-shares-in-neos-therapeutics-inc-neos-purchased-by-state-of-wisconsin-investment-board.html.

Neos Therapeutics Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics, Inc. (NASDAQ:NEOS).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply